Objectives:

Learning Objectives:

1. Present the rationale and clinical utility of TCR-engineered T cell immunotherapy for solid tumors
2. Review clinical evidence of TCR-engineered T cell immunotherapy in melanoma and synovial sarcoma
3. Discuss current and future investigational approaches with TCR-engineered T cell immunotherapy

and

1. Provide a brief overview of the epidemiology and biology of AML
2. Discuss the association of AML driver mutations with prognosis
3. Discuss utilization of novel prognostic models in risk stratification